After a long time, the new ESC Guidelines for the management of patients with supraventricular tachycardia are here

Eur Heart J Cardiovasc Pharmacother. 2020 Jan 1;6(1):3-5. doi: 10.1093/ehjcvp/pvz068.

Author

Affiliation

¹ Department of Pharmacology and Toxicology, School of Medicine, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERCV, Madrid, Spain.

PMID: 31800023
DOI: 10.1093/ehjcvp/pvz068

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Action Potentials / drug effects
Anti-Arrhythmia Agents / adverse effects
Anti-Arrhythmia Agents / therapeutic use*
Consensus
Heart Conduction System / drug effects*
Heart Conduction System / physiopathology
Heart Rate / drug effects*
Humans
Practice Guidelines as Topic / standards*
Tachycardia, Supraventricular / diagnosis
Tachycardia, Supraventricular / drug therapy*
Tachycardia, Supraventricular / physiopathology
Treatment Outcome

Substances

Anti-Arrhythmia Agents